Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Sell
42
BMRA Quote, Financials, Valuation and Earnings
Last price:
$2.61
Seasonality move
:
8.98%
Day range:
$2.60 - $2.81
52-week range:
$2.11 - $10.16
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.41x
P/B ratio:
1.33x
Volume:
76.6K
Avg. volume:
101.8K
1-year change:
3.85%
Market cap:
$6.9M
Revenue:
$5.3M
EPS (TTM):
-$1.53
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Biomerica, Inc. has 3751.85% upside to fair value with a price target of -- per share.
BMRA vs. S&P 500
-
Over the past 5 trading days, Biomerica, Inc. has overperformed the S&P 500 by 13.31% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Biomerica, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Biomerica, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Biomerica, Inc. reported revenues of $1.4M.
Earnings Growth
-
Biomerica, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Biomerica, Inc. reported earnings per share of $0.00.
Enterprise value:
4.2M
EV / Invested capital:
--
Price / LTM sales:
3.41x
EV / EBIT:
--
EV / Revenue:
0.86x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-1.50x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$636K
Return On Assets:
-51.74%
Net Income Margin (TTM):
-74.84%
Return On Equity:
-72.37%
Return On Invested Capital:
-65.36%
Operating Margin:
-81.02%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-08-31 | 2024-08-31 | 2025-08-31 | 2024-08-31 | 2025-08-31 | |
| Income Statement | ||||||
| Revenue | $5.4M | $5.5M | $4.9M | $1.8M | $1.4M | |
| Gross Profit | $913.1K | $485K | $636K | $289K | $424K | |
| Operating Income | -$6.4M | -$6.5M | -$4.9M | -$1.4M | -$1.1M | |
| EBITDA | -$6M | -$6.1M | -$4.5M | -$1.3M | -$1M | |
| Diluted EPS | -$1.26 | -$0.37 | -$1.53 | -$0.08 | $0.00 | |
| Period Ending | 2021-08-31 | 2022-08-31 | 2023-08-31 | 2024-08-31 | 2025-08-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $8.9M | $9.2M | $11.6M | $6.4M | $5.9M | |
| Total Assets | $11.5M | $11.1M | $13.2M | $7.9M | $6.9M | |
| Current Liabilities | $1.5M | $1.8M | $1.7M | $2.2M | $1.7M | |
| Total Liabilities | $2.7M | $2.7M | $2.5M | $2.5M | $1.7M | |
| Total Equity | $8.8M | $8.3M | $10.8M | $5.3M | $5.2M | |
| Total Debt | $1.2M | $970.9K | $705K | $373K | $6K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-08-31 | 2024-08-31 | 2025-08-31 | 2024-08-31 | 2025-08-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$5.6M | -$5M | -$2.8M | -$1.3M | -$268K | |
| Cash From Investing | -$107.4K | -$52K | -$37K | -- | -- | |
| Cash From Financing | $7.6M | -$81K | $3M | -- | $920K | |
| Free Cash Flow | -$5.7M | -$5.1M | -$2.8M | -$1.3M | -$268K | |
BMRA
Sector
Market Cap
$6.9M
$28.2M
Price % of 52-Week High
26.58%
50.25%
Dividend Yield
0%
0%
Shareholder Yield
-37%
-1.54%
1-Year Price Total Return
3.85%
-18.1%
Beta (5-Year)
0.060
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.45
200-day SMA
Sell
Level
$3.26
Bollinger Bands (100)
Sell
Level
2.46 - 3.1
Chaikin Money Flow
Sell
Level
-69.2M
20-day SMA
Buy
Level
$2.43
Relative Strength Index (RSI14)
Buy
Level
62.18
ADX Line
Buy
Level
23.71
Williams %R
Neutral
Level
-27.2727
50-day SMA
Buy
Level
$2.56
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
122.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-11.314)
Sell
CA Score
(Annual)
Level (-2.3027)
Buy
Beneish M-Score
(Annual)
Level (-3.4002)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (7.0725)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, North America, Asia, South America, and Middle East. The company was founded in September 1971 and is headquartered in Irvine, CA.
Stock Forecast FAQ
In the current month, BMRA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BMRA average analyst price target in the past 3 months is --.
-
Where Will Biomerica, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Biomerica, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Biomerica, Inc.?
Analysts are divided on their view about Biomerica, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Biomerica, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Biomerica, Inc.'s Price Target?
The price target for Biomerica, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BMRA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Biomerica, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BMRA?
You can purchase shares of Biomerica, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Biomerica, Inc. shares.
-
What Is The Biomerica, Inc. Share Price Today?
Biomerica, Inc. was last trading at $2.61 per share. This represents the most recent stock quote for Biomerica, Inc.. Yesterday, Biomerica, Inc. closed at $2.70 per share.
-
How To Buy Biomerica, Inc. Stock Online?
In order to purchase Biomerica, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BMRA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BMRA
Sector
P/E ratio
--
23.92x
PEG ratio
-0.01x
-0.01x
P/B ratio
1.33x
1.83x
Price / LTM sales
3.41x
1.61x
Growth Metrics
BMRA
Sector
Revenue growth
-23.63%
4.6%
Earnings growth
101.02%
10.88%
Revenue (5-year growth)
-4.52%
6.46%
Earnings forecast
--
-$0.21
Profitability
BMRA
Sector
Profitability FY 2025
$498K
$3.5M
Return on invested capital
-65.36%
-31.84%
Return on assets
-51.74%
-27.96%
Return on equity
-72.37%
-37.63%
Earnings Date
Last Earnings Date
Aug
30
Next Earnings Date
Dec
30
Estimated Next Earnings Date
Mar
31
Balance Sheet
BMRA
Sector
Total cash
$3.1M
$26.3M
Short term investments
--
$25.7M
Total assets
$5.9M
$76.9M
Long term debt
$6K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 29
Galecto, Inc. [GLTO] is down 12.13% over the past day.
Sell
20
SMX alert for Dec 29
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Sell
11
CDNAF alert for Dec 29
Canadian Tire Corp. Ltd. [CDNAF] is up 11.94% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
